Amrecibart and cenvacibart for the prevention of catheter-related thrombosis (ROXI-CATH): a double-blind, randomised, placebo-controlled, phase 2 trial
Amrecibart and cenvacibart for the prevention of catheter-related thrombosis (ROXI-CATH): a double-blind, randomised, placebo-controlled, phase 2 trial. // The Lancet Haematology. – URL: https://www.sciencedirect.com/science/article/pii/S2352302626002498?dgcid=rss_sd_all
Amrecibart and cenvacibart for the prevention of catheter-related thrombosis (ROXI-CATH): a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Haematology. https://www.sciencedirect.com/science/article/pii/S2352302626002498?dgcid=rss_sd_all
“Amrecibart and cenvacibart for the prevention of catheter-related thrombosis (ROXI-CATH): a double-blind, randomised, placebo-controlled, phase 2 trial.” The Lancet Haematology.
@article{article68449,
title = {Amrecibart and cenvacibart for the prevention of catheter-related thrombosis (ROXI-CATH): a double-blind, randomised, placebo-controlled, phase 2 trial},
journal = {The Lancet Haematology},
url = {https://www.sciencedirect.com/science/article/pii/S2352302626002498?dgcid=rss_sd_all}
}